Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) – Stock analysts at Jefferies Financial Group issued their FY2018 EPS estimates for Hikma Pharmaceuticals in a research note issued on Monday, October 15th, according to Zacks Investment Research. Jefferies Financial Group analyst J. Vane-Tempest forecasts that the company will post earnings of $1.21 per share for the year. Jefferies Financial Group also issued estimates for Hikma Pharmaceuticals’ FY2019 earnings at $1.25 EPS, FY2020 earnings at $1.32 EPS, FY2021 earnings at $1.41 EPS and FY2022 earnings at $1.49 EPS.
Separately, Zacks Investment Research cut Hikma Pharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $27.00 target price for the company. in a report on Wednesday, October 17th.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Further Reading: What are no-load funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.